A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Nov 2017

At a glance

  • Drugs TSR 042 (Primary)
  • Indications Endometrial cancer; Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms GARNET
  • Sponsors TESARO
  • Most Recent Events

    • 15 Nov 2017 Planned number of patients changed from 435 to 535.
    • 12 Sep 2017 Preliminary results (n=33; part I and part IIA) assessing safety, efficacy, receptor occupancy and pharmacokinetics of TSR-042, presented at the 42nd European Society for Medical Oncology Congress.
    • 11 Sep 2017 According to a a TESARO media release, patients with microsatellite instability high (MSI-H) and microsatellite stable endometrial cancer and non-small cell lung cancer are currently enrolling in the expansion phase of this study, and additional tumor types are planned for evaluation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top